View Older Stories View More Recent Stories

Jun 13, 2023 09:15AM Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
Jun 7, 2023 09:15AM Capricor Therapeutics (CAPR) Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy
Jun 7, 2023 09:15AM Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy
May 11, 2023 04:01PM Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 4, 2023 09:00AM Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11
Apr 27, 2023 09:00AM Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX™ Platform
Mar 23, 2023 09:25AM Capricor Therapeutics Presents at 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Mar 15, 2023 04:01PM Capricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Mar 8, 2023 09:00AM Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15
Mar 2, 2023 09:15AM Capricor Therapeutics Receives Clinical Research Forum’s 2023 Top Ten Clinical Research Achievement Award
Feb 16, 2023 09:25AM Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Japan
Jan 25, 2023 08:02AM Capricor Therapeutics (CAPR) Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients
Jan 25, 2023 08:00AM Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients
Jan 19, 2023 04:05PM Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Provide Recent Updates on CAP-1002 Program
Jan 12, 2023 09:33AM Capricor Therapeutics (CAPR) Reports Publication Highlighting New Advances for Exosome Platform
Jan 12, 2023 09:26AM Capricor Announces Publication Highlighting New Advances for its Engineered Exosome Platform
Nov 10, 2022 04:01PM Capricor Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Nov 3, 2022 04:01PM Capricor Therapeutics to Present Third Quarter 2022 Financial Results and Recent Corporate Update on November 10
Oct 6, 2022 09:00AM Capricor Therapeutics to Present One-Year Results from HOPE-2 Open Label Extension Study at World Muscle Society 2022
Sep 7, 2022 08:00AM Capricor Therapeutics to Present at Upcoming Investor Conferences
Aug 10, 2022 04:05PM Capricor Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Aug 3, 2022 08:00AM Capricor Therapeutics to Present Second Quarter 2022 Financial Results and Recent Corporate Update on August 10
Jul 19, 2022 09:15AM Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy
Jun 27, 2022 07:03AM Capricor Therapeutics (CAPR) Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with CAP-1002 in HOPE-2 Open
Jun 27, 2022 07:00AM Capricor Therapeutics Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with CAP-1002 in HOPE-2 Open Label
Jun 17, 2022 09:01AM Capricor Therapeutics (CAPR) to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular Dystrophy Annual Conference
Jun 17, 2022 09:00AM Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular Dystrophy Annual Conference
May 25, 2022 09:00AM Capricor Therapeutics Appoints Xavier Avat as Chief Business Officer
May 18, 2022 09:00AM Capricor Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 10, 2022 04:01PM Capricor Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 3, 2022 08:30AM Capricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10
Mar 29, 2022 09:00AM Capricor Therapeutics to Participate in the Cantor Fitzgerald Rare Orphan Disease Summit
Mar 28, 2022 08:30AM Capricor Therapeutics (CAPR) Reports Topline Results from Phase 2 Exploratory INSPIRE Trial in Severe Hospitalized COVID-19 Patients
Mar 28, 2022 08:30AM Capricor Therapeutics Reports Topline Results from Phase 2 Exploratory INSPIRE Trial in Severe Hospitalized COVID-19 Patients
Mar 11, 2022 08:02AM Capricor Therapeutics (CAPR) Reports Publication of Positive Results from Phase 2 Study Evaluating CAP-1002
Mar 11, 2022 08:00AM The Lancet Publishes Positive Results from Capricor Therapeutics’ Phase 2 Study Evaluating CAP-1002 in Late-Stage Duchenne Muscular Dystrophy
Mar 10, 2022 04:01PM Capricor Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Mar 3, 2022 09:15AM Capricor Therapeutics to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on March 10
Mar 2, 2022 09:00AM Capricor Therapeutics Names Dr. Daniel Paulson as Vice President of Clinical Development
Jan 25, 2022 05:54AM Capricor Therapeutics (CAPR) Partners with Nippon Shinyaku for Exclusive Commercialization and Distribution of CAP-1002
Jan 25, 2022 05:00AM Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in the U.S.
Dec 13, 2021 09:16AM Capricor Therapeutics (CAPR) Announces Updates on its Vaccine and Therapeutic Programs for COVID-19
Dec 13, 2021 09:15AM Capricor Therapeutics Announces Key Updates on its Vaccine and Therapeutic Programs for COVID-19
Nov 12, 2021 09:15AM Capricor’s CEO Dr. Linda Marbán to Serve as Keynote Speaker at TriLink Annual mRNA Day
Nov 9, 2021 04:05PM Capricor Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Nov 2, 2021 04:05PM Capricor Therapeutics to Present Third Quarter 2021 Financial Results and Recent Corporate Update on November 9
Sep 24, 2021 07:00AM Capricor Therapeutics (CAPR) Reports Positive Phase 2 HOPE-2 Trial Data in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002
Sep 24, 2021 07:00AM Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002
Sep 22, 2021 04:05PM Capricor Therapeutics to Present at the Upcoming Investor and Industry Healthcare Conferences
Sep 7, 2021 09:00AM Capricor Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
View More Recent Stories View Older Stories